跳至主要内容
临床试验/CTRI/2023/10/058636
CTRI/2023/10/058636尚未招募4 期

A Comparative study to Evaluate The Safety And Efficacy Of Saroglitazar As Monotherapy Vs Saroglitazar + Vitamin E Combination Therapy In The Management Of Non Alcoholic Fatty Liver Disease (NAFLD) - NI

MGM Medical College and Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients having Fatty Liver Grade 1 to 3 on USG
  • Ultrasound Attenuation Parameter more than 244 db./m.
  • Patients with F0 to F3 fibrosis on TE.
  • Individuals with BMI more than 23 kg per m2
  • Patient willing to participate in the study and give written informed consent

排除标准

  • Patients with significant alcohol consumption per day.
  • Patients with BMI less than 23 kg/m2.
  • Pre-diabetic patients and patients with known history of lean NASH.
  • Patients having F4 fibrosis on TE.
  • Patients having chronic viral hepatitis B and C.
  • Patients having other chronic liver diseases.
  • Patients having thyroid dysfunction or any metabolic disorder, except diabetes.
  • Patients taking any concurrent medications known to affect liver enzymes or CBC.
  • Patients showing intolerance to Saroglitazar and Vitamin E.
  • Pregnant and Lactating women.
  • Patients not willing to participate in the study and give written informed consent.

研究者

相似试验